The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in respiratory illness:

PROTOCOL: Z7224L02 (PI: DR RACHEL THOMSON)

SHORT TITLE: THE PROMIS II STUDY
Protocol Title: A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)

Lay Title: Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium. (PROMIS-II)

Click here for more information

 

PROTOCOL: IM027-040 (PI: DR RACHEL THOMSON)

Protocol Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

Lay Title: A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Click here for more information

 

PROTOCOL: INS415 (ARISE) (PI: DR RACHEL THOMSON)

Protocol Title: A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

Lay Title: Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Myobacterial Lung Infection Caused by Myobacterium Avium Complex (ARISE)

Click here for more information

 

PROTOCOL: INS416 (ENCORE) (PI: DR RACHEL THOMSON)

Protocol Title: A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

Lay Title: Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (ENCORE)

Click here for more information

 

PROTOCOL: BA__NTM_AU_CP_01.01 (PI: DR RACHEL THOMSON)

Protocol Title: A Pilot Study to Assess the Effect of Intermittent Nitric Oxide on the Treatment of Nontuberculous Mycobacteria (NTM) Lung Infection in Cystic Fibrosis and Non-Cystic Fibrosis Patients

Lay Title: Inhaled NO for the Treatment of Nontuberculous Mycobacteria (NTM) Lung Infection in Cystic Fibrosis and Non-Cystic Fibrosis Patients

Click here for more information

 

PROTOCOL: INS1007-301 (ASPEN) (PI: DR RACHEL THOMSON)

Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis

Lay Title: A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Click here for more information

 

RETURN TO CLINICAL TRIALS PAGE